Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
PHAT 
Phathom Pharmaceuticals Inc (PHAT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/09/2025: PHAT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $22.33
1 Year Target Price $22.33
| 6 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 23.04% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.01B USD | Price to earnings Ratio - | 1Y Target Price 22.33 |
Price to earnings Ratio - | 1Y Target Price 22.33 | ||
Volume (30-day avg) 9 | Beta 0.43 | 52 Weeks Range 2.21 - 16.27 | Updated Date 12/10/2025 |
52 Weeks Range 2.21 - 16.27 | Updated Date 12/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.76 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -186.53% | Operating Margin (TTM) -30.85% |
Management Effectiveness
Return on Assets (TTM) -42.54% | Return on Equity (TTM) -3489% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1085528232 | Price to Sales(TTM) 6.87 |
Enterprise Value 1085528232 | Price to Sales(TTM) 6.87 | ||
Enterprise Value to Revenue 7.38 | Enterprise Value to EBITDA -2.2 | Shares Outstanding 71138440 | Shares Floating 50304823 |
Shares Outstanding 71138440 | Shares Floating 50304823 | ||
Percent Insiders 4.5 | Percent Institutions 87.77 |
Upturn AI SWOT
Phathom Pharmaceuticals Inc
Company Overview
History and Background
Phathom Pharmaceuticals Inc. was founded in 2020. It is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) and other diseases. The company has made significant strides in bringing innovative therapies to patients, particularly in the area of Helicobacter pylori (H. pylori) infection.
Core Business Areas
- Gastrointestinal Disease Therapeutics: Phathom Pharmaceuticals is primarily focused on developing and commercializing treatments for gastrointestinal diseases. Their lead candidate targets a significant unmet need in the treatment of Helicobacter pylori infection.
Leadership and Structure
Phathom Pharmaceuticals is led by a seasoned management team with extensive experience in the pharmaceutical industry. The company operates as a publicly traded entity, structured with standard corporate governance.
Top Products and Market Share
Key Offerings
- vonoprazan: Vonoprazan is Phathom Pharmaceuticals' lead product candidate, a potassium-competitive acid blocker (P-CAB). It is being developed for the treatment of H. pylori infection, with potential applications in other acid-related disorders. Competitors in the H. pylori space include proton pump inhibitors (PPIs) and antibiotics. Specific market share data for vonoprazan is not yet established as it is in late-stage development and seeking regulatory approval.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the gastrointestinal therapeutics sector, is characterized by significant innovation and a constant need for improved treatment options. The market for H. pylori treatment is substantial, with challenges in current eradication rates due to antibiotic resistance.
Positioning
Phathom Pharmaceuticals is positioned as an innovator in the GI space, aiming to address unmet medical needs with its novel P-CAB technology. Its focus on H. pylori offers a differentiated approach to a prevalent infection.
Total Addressable Market (TAM)
The TAM for H. pylori treatment is significant, with millions of individuals affected globally. Phathom Pharmaceuticals is positioned to capture a substantial portion of this market with a potentially more effective therapy. Specific TAM figures are subject to ongoing market research and epidemiological data.
Upturn SWOT Analysis
Strengths
- Novel drug candidate (vonoprazan) with a differentiated mechanism of action.
- Experienced management team.
- Focus on a significant unmet medical need (H. pylori infection).
Weaknesses
- Reliance on a single lead product candidate.
- As a relatively young company, it may have limited brand recognition.
- Potential challenges in securing market access and reimbursement.
Opportunities
- High prevalence of H. pylori infection globally.
- Growing antibiotic resistance necessitates new treatment approaches.
- Potential for vonoprazan to be used in other acid-related disorders.
- Strategic partnerships and collaborations.
Threats
- Regulatory hurdles and approval timelines.
- Competition from existing treatments and other pipeline drugs.
- Pricing pressures from payers.
- Potential for unexpected clinical trial outcomes.
Competitors and Market Share
Key Competitors
- Takeda Pharmaceutical Company (TAK)
- AbbVie Inc. (ABBV)
- Pfizer Inc. (PFE)
Competitive Landscape
Phathom Pharmaceuticals' competitive advantage lies in its innovative P-CAB technology, which aims to overcome limitations of current therapies for H. pylori. However, it faces established players with broad portfolios and significant market presence.
Growth Trajectory and Initiatives
Historical Growth: Phathom Pharmaceuticals is in its early growth phase, with historical growth primarily driven by its transition to a publicly traded company and advancement of its lead candidate through clinical trials.
Future Projections: Future projections for Phathom Pharmaceuticals are contingent on the successful regulatory approval and commercialization of vonoprazan. Analyst estimates will focus on potential peak sales and market penetration.
Recent Initiatives: Key recent initiatives include the advancement of vonoprazan through Phase 3 clinical trials and regulatory submissions, as well as ongoing business development efforts.
Summary
Phathom Pharmaceuticals Inc. is a promising clinical-stage biopharmaceutical company with a strong focus on gastrointestinal therapeutics, particularly H. pylori infection. Its lead candidate, vonoprazan, represents a novel approach with the potential to address significant unmet medical needs. The company's success hinges on navigating regulatory pathways and effectively competing against established pharmaceutical giants. Key watch points include trial outcomes, regulatory approvals, and market adoption.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Industry research reports
- Financial news outlets
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Market share data is illustrative and subject to change. Investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Phathom Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Florham Park, NJ, United States | ||
IPO Launch date 2019-10-25 | CEO, President & Director Mr. Steven L. Basta M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 427 | Website https://www.phathompharma.com |
Full time employees 427 | Website https://www.phathompharma.com | ||
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.